Highlander Capital Management »

Protalix Biotherapeutics shares owned by Highlander Capital Management

Quarter-by-quarter ownership of Protalix Biotherapeutics (PLX) shares owned by Highlander Capital Management from 13F filings

Historical chart of Highlander Capital Management investment in Protalix Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Protalix Biotherapeutics held by Highlander Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Protalix Biotherapeutics by Highlander Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $1.1k 610 1.78
2023-09-30 $999 610 1.64

More positions owned by Highlander Capital Management

Unitedhealth Group Equities (UNH)
Apple Equities (AAPL)
Microsoft Corp Equities (MSFT)
Berkshire Hathaway Equities (BRK.B)
Stryker Corp Common Equities (SYK)
Amgen Equities (AMGN)
Home Depot Equities (HD)
Cnx Res Corp Equities (CNX)
Alphabet Inc Cap Stk Cl C Equities (GOOG)
Parker-hannifin Corp Equities (PH)
Costco Wholesale Corp Equities (COST)
Jpmorgan Chase & Co Equities (JPM)
Ingredion Equities (INGR)
Bank New York Mellon Corp Equities (BK)
Cisco Sys Equities (CSCO)

View all positions for Highlander Capital Management

Top funds holding Protalix Biotherapeutics

GSA Capital Partners
Vanguard Group
Bank of America Corporation
Bank of New York Mellon
Charles Schwab Investment Management
Barclays
Goldman Sachs Group
Citadel Advisors
Orin Green Financial
UBS Group
OZ Management
Rhumbline Advisers
Connor, Clark & Lunn Investment Management
Bailard
Commonwealth Equity Services

View all funds holding Protalix Biotherapeutics